Editorial
A New Generation of Coronary Vasodilators in Stress Perfusion Imaging

https://doi.org/10.1016/j.amjcard.2006.06.062Get rights and content

Section snippets

Selective A-2a Agonists

Currently, there are 3 such agents in phase III clinical trials. These agents are hoped to have the desirable features but none of the side effects of adenosine, because that is what selectivity implies. These agents are regadenoson, binodenoson, and apadenoson. A forth agent (CGS21680) was studied only in an animal model and is not likely to enter clinical testing.8 The 3 agonists share a common feature of selectivity, but they do differ in affinity, onset of action, duration of hyperemia, and

Cited by (10)

  • Therapeutic potential of adenosine analogues and conjugates

    2011, Pharmacological Reports
    Citation Excerpt :

    However, further studies are required to improve its affinity and selectivity to A2A. Selective A2A adenosine receptor agonists are a new class of coronary vasodilators used in stress perfusion imaging with radiotracers [47]. The myocardial perfusion imaging stress test is a noninvasive way to assess blood flow to the heart muscle to detect coronary artery disease.

  • Coronary Artery Disease Detection: Pharmacologic Stress SPECT. Pharmacologic Stress SPECT.

    2010, Clinical Nuclear Cardiology: State of the Art and Future Directions
  • Safety of regadenoson as a pharmacologic stress agent in patients with chronic kidney and pulmonary disease

    2016, Myocardial Perfusion Imaging (MPI): Performance, Potential Risks and Outcomes
View all citing articles on Scopus
View full text